On Wednesday 6th July UCLH are hosting a web chat with Consultant Haematologist Dr Beth Payne from 12-1pm. The conversation will focus on managing MDS from the point of diagnosis through to treatment and Dr Payne will be on hand to answer your questions.
Myelodysplastic syndrome (MDS), or myelodysplasia, is a blood disorder that causes a drop in your number of healthy blood cells. MDS covers a spectrum of disorders from indolent (slow developing) to aggressive (that rapidly develop or change into leukaemia).
MDS can affect people of any age, but is most common in people over the age of 65. Only one in five people with MDS are younger than 50. For most people, symptoms are mild at first and slowly get worse. Sometimes you may even have no symptoms at all, but have had a blood test that shows there is a problem. The treatment of MDS is constantly evolving and new drugs are being tested all the time.
Dr Payne is a Consultant Haematologist at UCLH and specialises in treating patient with MDS and bone marrow failure. As a Senior Clinical Researcher funded by the Wellcome Trust and The Leuka John Goldman Fellowship for future Science, Dr Payne runs a research laboratory studying the mechanisms of disease in bone marrow failure and myelodysplastic syndromes and is also working to develop novel therapeutics.
Questions related to all aspects of myelodysplastic syndromes and related conditions are welcome and you can send queries in advance to email@example.com. To join in on the conversation on Wednesday 6th, visit UCLH’s website here: https://www.uclh.nhs.uk/aboutus/webchat/Pages/myelodysplasticsyndromes.aspx.